JMI XII Executive

Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.

1 partner is named across this firm’s filings, 1 of them on a fund it is deploying now.

Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.

Classified sectors of JMI XII Executive’s own portfolio companies, based on 23 with a verified or cited source.

• Enterprise software4 · 17%
• Digital health3 · 13%
• Manufacturing & industrials3 · 13%
• Medical devices2 · 9%
• Sales & marketing tech2 · 9%
• Telecom & networking2 · 9%
• AI & machine learning1 · 4%
• Biotech & pharma1 · 4%
• Climate & energy1 · 4%
• Cybersecurity1 · 4%
• Fintech1 · 4%
• Food & agriculture1 · 4%
• Healthcare services1 · 4%

Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of JMI XII Executive’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.

No other firm shares a filed board seat with JMI XII Executive yet. That is a gap in what we have read, not a claim that JMI XII Executive invests alone.

A shared board seat: a company where filings name a JMI XII Executive partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.